Disclosure of competing financial interests and role of sponsors in phase III cancer trials

European Journal of Cancer

Volumn 41, Issue 15, 2005, Pages 2237-2240

  Tuech, Jean Jacques ^a,b   Moutel, Grégoire ^a   Pessaux, Patrick ^c   Thoma, Véronique ^d   Schraub, Simon ^a,d   Herve, Christian ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d Paul Strauss Centre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INDUSTRY; ECONOMIC ASPECT; EMPLOYMENT; INTERPERSONAL COMMUNICATION; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; RESEARCH ETHICS;

CLINICAL TRIALS, PHASE III; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH SUPPORT;

EID: 26244442420     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.12.036     Document Type: Article

References (32)

1. D.F. Thompson Understanding financial conflicts of interest N Engl J Med 329 8 1993 573 576
2. D. Blumenthal Ethics issues in academic industry relationships in the life science Acad Med 71 1996 1291 1296
3. T. Bodenheimer Uneasy alliance - clinical investigators and the pharmaceutical industry N Engl J Med 342 2000 1621 1626
4. International Committee of Medical Journal Editors Conflict of interest Lancet 341 1993 742 743
5. International Committee of Medical Journal Editors Uniform requirements for manuscripts submitted to biomedical journals Ann Intern Med 126 1997 36 47
6. A. Hussain, and R. Smith Declaring financial competing interests: survey of five general medical journals BMJ 323 2001 263 264
7. The International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial Lancet 360 2002 505 515
8. M.J. Langman, J.A. Dunn, and J.L. Whiting Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group Brit J Cancer 81 1999 1356 1362
9. S.R. Bramhall, M.T. Hallissey, and J. Whiting Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial Brit J Cancer 86 2002 1864 1870
10. R. Rosell, U. Gatzemeier, and D.C. Betticher Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann Oncol 13 2002 1539 1549
11. T.J. Littlewood, E. Bajetta, and J.W. Nortier Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865 2874
12. J.M. Kurie, R. Lotan, and J.J. Lee Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial J Natl Cancer Inst 95 2003 206 214
13. M.L. Rothenberg, A.M. Oza, and R.H. Bigelow Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2003 2059 2069
14. S. Faiss, U.F. Pape, and M. Bohmig Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696
15. H.C. Schouten, W. Qian, and S. Kvaloy High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial J Clin Oncol 21 2003 3918 3927
16. F. Cardenal, M.P. Lopez-Cabrerizo, and A. Anton Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 17 1999 12 18
17. J.M. Nabholtz, H.J. Senn, and W.R. Bezwoda Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 17 1999 1413 1424
18. S.S. Agarwala, J. Glaspy, and S.J. O'Day Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma J Clin Oncol 20 1 2002 125 133
19. S.R. Cummings, T. Duong, and E. Kenyon Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene JAMA 287 2002 216 220
20. J. Sjostrom, C. Blomqvist, and H. Mouridsen Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group Eur J Cancer 35 1999 1194 1201
21. H. Mouridsen, M. Gershanovich, and Y. Sun Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 2001 2596 2606
22. French Adjuvant Study Group Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group05 randomized trial J Clin Oncol 19 2001 602 611
23. H. Kantarjian, C. Sawyers, and A. Hochhaus Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
24. G.D. Demetri, M. von Mehren, and C.D. Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
25. T.J. Smith, P.S. Staats, and T. Deer Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival J Clin Oncol 20 2002 4040 4049
26. S.G. O'Brien, F. Guilhot, and R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
27. C.J. Punt, A. Nagy, and J.Y. Douillard Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study Lancet 360 2002 671 677
28. R. Smith Beyond conflict of interest. Transparency is the key BMJ 317 1998 291 292
29. H. Moses 3rd, E. Braunwald, and J.B. Martin Collaborating with industry - choices for the academic medical center N Engl J Med 347 2002 1371 1375
30. S. Lewis, P. Baird, and R.G. Evans Dancing with the porcupine: rules for governing the university-industry relationship CMAJ 165 2001 783 785
31. K.A. Schulman, D.M. Seils, and J.W. Timbie A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors N Engl J Med 347 2002 1335 1341
32. F. Davidoff, C.D. DeAngelis, and J.M. Drazen Sponsorship, authorship, and accountability Lancet 358 2001 854 856